A PHASE II, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF THE COMBINATION OF INAVOLISIB PLUS ENZALUTAMIDE VERSUS PHYSICIAN'S CHOICE OF ARPI OR DOCETAXEL IN PATIENTS WITH METASTATIC CASTRATIONRESISTANT PROSTATE CANCER
- Registry ID
- CO45813
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Start date
- 2025-12-22
- Last update
- 2025-09-23
Conditions
Related clinical trials
- A PHASE I/II OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF AZD6621, A T -CELL-ENGAGING ANTIBODY THAT TARGETS STEAP2, CD3, AND CD8 IN ADULT PARTICIPANTS WITH METASTATIC PROSTATE CANCER (ACTIVATED-4-PC)
- Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
- A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE OPTIMIZATION STUDY OF GSK5471713 IN ADULT PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
- A PHASE 1/2 PLATFORM
STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IFINATAMAB DERUXTECAN AS
MONOTHERAPY OR IN COMBINATION WITH OTHER TREATMENTS IN PARTICIPANTS
WITH PROSTATE CANCER
- FOUR-TIMEPOINT MULTI-TRACER PET IMAGING TO CHARACTERIZE METASTATIC PROSTATE CANCER HETEROGENEITY (4TMPO)
- A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF OPEVESOSTAT VERSUS ALTERNATIVE ABIRATERONE ACETATE OR ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATIONRESISTANT PROSTATE CANCER (MCRPC) THAT PROGRESSED ON OR AFTER PRIOR TREATMENT WITH ONE NEXT- GENERATION HORMONAL AGENT (NHA) (OMAHA-004)
View on source registry